 |
인쇄하기
취소
|
Boehringer Ingelheim Korea releases telmisartan and hydrochlorothiazide combination drug
Boehringer Ingelheim Korea says it has recently launched Micardis Plus (telmisartan 80mg/hydrochlorothiazide 25mg).
The combination drug is indicated for the treatment of mild to moderate hypertension in patients that have failed to achieve the desired antihypertensive effect through monotherapy.
The fixed dose combination is not indicated as initial therapy and is reserved for patients ...
The combination drug is indicated for the treatment of mild to moderate hypertension in patients that have failed to achieve the desired antihypertensive effect through monotherapy.
The fixed dose combination is not indicated as initial therapy and is reserved for patients ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.